Summary: The lack of clinical activity from various immune-checkpoint blockade approaches in mismatch repair– proficient (MMRp) colorectal cancer has demonstrated a critical need for novel approaches. In this issue, Crisafulli and colleagues provide proof of concept for the induction of hypermutability through the use of temozolomide as a potential pathway for enabling a productive anti–PD-1 immune response in MMRp colorectal cancer. See related article by Crisafulli et al., p. 1656 (1) .

中文翻译：

---

诱导超突变以促进抗 PD-1 治疗反应

摘要：各种免疫检查点阻断方法在错配修复（MMRp）结肠直肠癌中缺乏临床活性，这表明迫切需要新的方法。在本期中，Crisafulli 及其同事通过使用替莫唑胺作为在 MMRp 结直肠癌中实现有效的抗 PD-1 免疫反应的潜在途径，提供了诱导超突变性的概念证明。请参阅 Crisafulli 等人的相关文章，第 17 页。1656（1）。